NasdaqGS:BMRNBiotechs
BioMarin (BMRN): Valuation in Focus After New VOXZOGO and PALYNZIQ Study Results Boost Confidence
BioMarin Pharmaceutical (BMRN) just put a major spotlight on its pipeline by revealing fresh results from 14 studies on its flagship therapy VOXZOGO at the ASBMR 2025 meeting. The company also delivered new efficacy and safety data for PALYNZIQ at another global conference, rounding out a week marked by clinical validation for its key rare disease drugs. For investors trying to make sense of what this flurry of data means, the updates do more than just celebrate milestones; they potentially...